Drugs / Hema-NeoTIL01
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 0 | NCT06559644 | Sep 2024 → Sep 2026 overdue | B-cell acute lymphoblastic leukemia, acute myeloid leukemia | The First Affiliated Hospital of Soochow University | Not yet recruiting | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Hema-NeoTIL01 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT06559644 ↗ |
| Modality | Cell therapy | “autologous tumor-specific T cells” NCT06559644 ↗ |
| Route | Intravenous | “Patients will receive intravenous infusion of Hema-NeoTIL01” NCT06559644 ↗ |